Genmab nine-month operating profit falls to $986 million; revenue rises 22% to $3.24 billion
GMAB•Genmab’s operating profit fell to $986 million in the first nine months of 2026, while revenue rose 22% to $3.24 billion. The company maintained its 2026 financial guidance.
1. Nine-month results
Genmab’s operating profit fell to $986 million in the first nine months of 2026, while revenue rose 22% to $3.24 billion, helped by higher DARZALEX and Kesimpta royalties. Operating expenses climbed 35% to $2.02 billion. Genmab said October brought positive Phase 3 topline results for epcoritamab, Rina-S and petosemtamab, supporting plans to engage regulators, and maintained its 2026 financial guidance published August 6.
